Trial Profile
An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 May 2022
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-099
- Sponsors Eli Lilly and Company
- 11 Sep 2020 Study design changed from Single Group Assignment to Sequential Assignment.
- 03 Oct 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Planned End Date changed from 20 Jun 2019 to 20 Dec 2019.